Search 

Venn Biosciences innovates cancer diagnostics using Artificial Intelligence (AI) and next-gen mass spectrometry, unlocking glycoproteomics for Biomarker and Target Discovery.

InvivoSciences, Inc. (IVS) is a preclinical stage biotech company with a team of drug development experts, including Dr. Joseph Schlessinger, who developed various therapies including, a blockbuster drug - Sutent.
With an increasingly aging population with chronic diseases such as diabetes, heart failure is an urgent and critical challenge without an effective solution. There have been no successful phase III trials in worsening chronic heart failure or heart failure with preserved ejection fraction (HFpEF). Large clinical trials required for the heart failure trials have been the bottleneck. There is clear evidence showing that genetic factors drive heart failure development. Our mission is to cure heart failure one gene at a time.
We have leveraged our advanced artificial intelligence integrated breakthrough in precision medicine discovery platform using patient-derived human micro heart on a chip, NuHeart™, to identify and validate multiple drug pipelines rapidly as well as help us to determine biomarkers and stratify the patients for a clinical trial recruitments. Our precision heart failure pipelines are at least ten times more cost-effective to develop, especially during their clinical stages. Using our platform, we have developed two pipelines of small-molecule candidates for difficult to treat, genetically defined heart failure conditions. Our Pipelines of precision medicines have the potential to deliver better outcomes for patients fighting hard to treat heritable heart disease.
Collaborative patient-driven precision medicine-based drug development empowered with our novel platform will lead to meaningfully better outcomes for heart failure patients, which we refer to as InvivoSciences’ discovery engine to develop target therapies. Our lead program includes candidates in preclinical development for monogenetic heart failures. To date, IVS raised $8.5 Million non-dilutive funding from founders, board, commercial contracts, and grants. The funds have been used to create a portfolio of assets (breakthrough discovery platform, NuHeart™, three genetically defined disease models, current discovery programs, and a strong portfolio of patents including both US and international.
To join and support our drug discovery programs forward, InvivoSciences is seeking world-class life science investors and strategic partners for our Series A round for growth capital for $10 M in two trunches for commercial growth and accelerating our drug program.

iX Biopharma is established in 2008, and listed on Singapore Stock Exchange (Catalist Board) in 2015. iX is a specialist in novel wafer formulations using patented sublingual delivery technology, WaferiXTM , which is patented in China to 2033. R&D and manufacturing at wholly-owned GMP licensed facility in Melbourne, Australia.

Jiangsu Carephar Pharmaceutical Co.,Ltd

Founded in 2009, Kintor Pharmaceuticals concentrates on the R&D and industrialization of “best-in-class” and “first-in-class” innovative drugs and strives to become a leading enterprise in the R&D and commercialization of innovative therapies. On 22 May 2020, Kintor Pharmaceuticals was officially listed on the Hong Kong Stock Exchange with the stock code 9939.HK.

Kymeris has invented a revolutionary, live-cell based technology platform which delivers into the tumor micro-environment and activates there multiple therapeutic agents - including ligands, cytokines, and antibodies. Efficacy of anti-cancer action has been shown in 5 separate solid cancer indications with reduction in tumour size averaging 80% - but in many cases showing complete eradication. This game changing approach is of particular value to companies with proprietary molecules that are looking for safe and effective vectoring into tumors, and with whom we might partner.

Our goal is to advance the development of analytical technologies by combining our specialist knowledge from chemistry, biology, physics and computer science and the transfer of our results to science, business and the public are our main goals.

Libera Bio develops a new family of cancer treatments based on its patented actively targeted delivery technology to intracellular targets (MPN – Multifunctional Polymeric Nanocapsules) and on novel monoclonal antibodies (e.g. anti KRAS), with the goal to have them commercialized by large biopharma companies after regulatory approval for clinical trials or early proof-of-concept in humans.

Libera Bio lead candidate aims at providing a new treatment for those highly prevalent and aggressive cancers which are driven by KRAS mutations, such as pancreatic cancer, lung cancer and colorectal cancer.

LinkedUp Bio, pioneered a novel antibody drug discovery engine that is dedicated to developing novel biological therapeutics for diseases that have limited or no successful treatment.
The gamechanger element is that we can scree the entire natural immune repertoire with unprecedented speed and scales and identified hits rapidly and efficiently, thereby greatly increasing the success rate of potential therapeutics for targets that are hard to drug.

AbLink Platform: Screening the entire immune repertoire for more efficient antibody discovery
LInkedUp Bio is using microfluidic device to enable single B cell encapsulation, and subsequently, extract the information of heavy chain and light chain of antibody from tens of millions of B cells and then transferred them into our in-house engineered yeast system. These antibody copies in the yeast cells maintained their natural heavy chaiin and light chain pair, and good biophysical stabilities of the original B cells. Our yeast strain has both display and secretion mode which enables quick chacterization of the potential hits, eliminating the step for mamamlian expression for further hits validation, a typical bottleneck for many single B cell platfrom.

The AbLink Platform is the only platform allowing comprehensive screening of the natural antibody repertoire. This results in at least 100 times more hits than hybridoma and other single B cell platforms. Other benefits include more extensive epitope coverage, more unique and rare sequences & diversity, higher affinity, and functionality. Currently the platform gathered a great deal of interest in industry as we already collaborated with two biopharmas and several others are in the middle of conversation.

LUB-001 : Tackling malignant melanoma and solid tumors
LinkedUp Bio’s first target indication is malignant melanoma, one of the deadliest forms of human cancer, due to the high incidence of metastases and drug resistance. Extensive research supports the role of a new target X for malignant melanoma, potentially affecting tumor growth, survival and metastasis. However, due to the limitations of traditional antibody discovery technologies and the complex structure of the target, there have been numerous antibody candidates that showed limited efficacy in inhibition of tumor growth, never matched the high expectation and promise of a breakthrough treatment.
LinkedUp developed a novel antibody clone for this target X and in vitro data demonstrated drastically improvement of the ability of the immune system to attack the tumor cells. LinkedUp Bio’s approach can provide a novel promising treatment for many different types of cancer, such as triple negative breast cancer, glioblastoma, hepatocellular carcinoma, and more.
LUB-002: Tackling congenital muscular dystrophy
Alpha Dystrolycanopathy is a clinically and genetically heterogeneous group of muscular dystrophies with the defective matriglycan which links the muscle cells with extracellular matrix . The cause of the defection involved more than 18 genes, and manifested various degree of severity in clinical symptoms. Currently there no effective therapy for this group of diseases. Novel strategies like antisense, AAV gene therapy, enzyme replace can only address one kind gene a time, making a significant commercial challenge. We propose a novel bispecific antibody approach that functions as a surrogate molecular linker to reconnect extracelluar matrix and the muscle cells to ameliorate sarcolemmal fragility, a primary pathology in patients with alpha-dystroglycan- related muscular dystrophies.

We are currently seeking fund to move our program forward and expand our team.

Team:
Greg Li, Co-founder, President
Stephen Gillies, Co-founder, CSO
Tao Wang, Co-founder, Vice President of Antibody Discovery

Jason Lavinder, Cofounder, Advisory Board